ACTA1 and neoplasm: Franco et al., by the use of a genetically engineered mouse model of pancreatic neuroendocrine tumors, demonstrated the utility of α-smooth muscle actin (α-SMA), expressed by pericytes surrounding tumor co-opted vessels, as surrogate marker for response or evasive resistance to anti-angiogenic therapy [22].